4 ms·
When covid-19 first popped up, it seemed the time from sequencing to first trials of vaccinations was in the order of weeks. This mRNA tech is just incredible t
by mabbo 5y ago
When covid-19 first popped up, it seemed the time from sequencing to first trials of vaccinations was in the order of weeks. This mRNA tech is just incredible that way.
Is anyone making and testing new vaccines that address the new variants? One would expect the variants just have a few key protein changes, which could be vaccinated against.
And more importantly, do we see any hope of accelerated timelines for nearly identical vaccines that target slightly different proteins?
- rsfern 5y agoModerna is starting development on an omicron-specific vaccine, as well as testing their other vaccine variants. I wonder if maybe the manufacturing data required for approval could be expedited in these sort of minor vaccine version updates? https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-strategy-address-omicron-b11529-sars-cov-2 https://investors.modernatx.com/news-releases/news-release-d...
- mdp2021 5y ago> Moderna is starting development on an omicron-specific vaccine Also the Novavax producers. RSS feeds hours ago were full of "ready in 100 days" expressions; as I am making posts-vetting checks on search engines I am seeing one «would have the shot ready for testing and manufacturing in the next few weeks» (https://www.straitstimes.com/world/united-states/novavax-testing-vaccine-that-targets-new-omicron-covid-19-variant https://www.straitstimes.com/world/united-states/novavax-tes...).
- jeremyjh 5y agoDo we know that a "minor version update" could never cause a problem like the 1976 Swine Flu vaccine that was rushed to mass deployment and killed far more people than that flu did?
- rsfern 5y agoRight, there’s not way to know that without the clinical trials that are required even for small formulation changes, our quantitative understanding of biology is not that good. But there’s plenty of supply chain and manufacturing aspects of the approval that seem like wouldn’t need any more stringency than the ongoing monitoring for the currently approved vaccines, from my lay persons perspective anyway
- vmception 5y agoI’m not even sure what forum to discuss this on anymore given so many variables Headlines be like “[last year’s] vaccine less effective against [this year’s] variant” but omitting everything in the brackets when this is an obvious standard used for every seasonal pathogen….. I’m also curious about who is doing what